By Fineline Cube 
China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.
Company Overview
GenFleet is a clinical-stage biopharmaceutical company focused on developing novel drugs for oncology, autoimmune, and inflammatory diseases. It has established a pipeline of eight drug candidates, five of which are in clinical development, and three are in preclinical research.
Product Highlights
Fulzerasib (GFH925), a selective KRAS G12C inhibitor, received approval in China in December 2023 for treating advanced non-small cell lung cancer (NSCLC) that has progressed after standard therapy. This makes it the first of its kind in China. GFH375, a small molecule KRAS G12D inhibitor, is currently undergoing Phase I/II studies in China for advanced solid tumors with the KRAS G12D mutation.
Innovative Programs
The company is advancing several novel-target programs, including GFS202A, a GDF15/IL-6 bispecific antibody (BsAb), and GFH312, an RIPK1 kinase inhibitor. GFH312 has received approval for studies in peripheral artery disease and primary biliary cholangitis in the US and China.
Financial Performance
In the first four months of this year, GenFleet reported revenues of RMB 82.15 million (USD 11.47 million) and a loss of RMB 66.62 million (USD 9.3 million).-Fineline Info & Tech